Phase 3 TRIUMPH-4 showed 28.7% weight loss at 68 weeks, substantially exceeding CagriSema's 20.4% at 68 weeks
Common reported effects in clinical use include mild injection site reactions with subcutaneous administration, occasional digestive changes when taken orally, and rare reports of fatigue or dizziness
The Synthesis of a Tetrapeptide
13036_2026_630_MOESM1_ESM.docx (download DOCX Supplementary Material 1: The supplementary data of this article includes: control logic diagram of AR-AST System, comprehensive facility diagram, real-time monitoring performance verification, experimental strains, experimental execution standards, experimental instruments, drug resistance identification standards, etc
This synthetic peptide, derived from the fragment 177-191 of human growth hormone (hGH), is designed to selectively stimulate fat metabolism without engaging growth hormone receptors that influence tissues beyond fat cells (2)